Hayek Kallen Investment Management Invests $99,000 in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Hayek Kallen Investment Management bought a new stake in Anavex Life Sciences Corp. (NASDAQ:AVXLFree Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 10,673 shares of the biotechnology company’s stock, valued at approximately $99,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AVXL. BNP Paribas Financial Markets increased its stake in Anavex Life Sciences by 34.2% during the 4th quarter. BNP Paribas Financial Markets now owns 111,032 shares of the biotechnology company’s stock worth $1,034,000 after buying an additional 28,297 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Anavex Life Sciences by 2.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 622,310 shares of the biotechnology company’s stock worth $5,794,000 after acquiring an additional 17,499 shares in the last quarter. Los Angeles Capital Management LLC boosted its holdings in Anavex Life Sciences by 187.3% in the fourth quarter. Los Angeles Capital Management LLC now owns 58,087 shares of the biotechnology company’s stock valued at $541,000 after purchasing an additional 37,867 shares during the last quarter. Victory Capital Management Inc. acquired a new stake in Anavex Life Sciences during the 4th quarter valued at approximately $100,000. Finally, New York State Common Retirement Fund increased its holdings in Anavex Life Sciences by 10.0% during the 4th quarter. New York State Common Retirement Fund now owns 29,321 shares of the biotechnology company’s stock worth $273,000 after purchasing an additional 2,670 shares during the last quarter. 31.55% of the stock is owned by institutional investors and hedge funds.

Anavex Life Sciences Trading Up 1.1 %

AVXL stock traded up $0.05 during mid-day trading on Friday, hitting $4.55. 942,737 shares of the company were exchanged, compared to its average volume of 1,171,921. The firm has a fifty day simple moving average of $4.34 and a 200 day simple moving average of $5.82. The company has a market capitalization of $385.11 million, a PE ratio of -9.10 and a beta of 0.66. Anavex Life Sciences Corp. has a twelve month low of $3.25 and a twelve month high of $10.45.

Anavex Life Sciences (NASDAQ:AVXLGet Free Report) last posted its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.13) EPS for the quarter, hitting analysts’ consensus estimates of ($0.13). During the same period last year, the company earned ($0.17) earnings per share. As a group, sell-side analysts anticipate that Anavex Life Sciences Corp. will post -0.55 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Anavex Life Sciences in a research note on Friday, May 10th.

Get Our Latest Stock Analysis on Anavex Life Sciences

Insider Activity at Anavex Life Sciences

In other Anavex Life Sciences news, CEO Christopher U. Missling sold 73,380 shares of Anavex Life Sciences stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $5.11, for a total value of $374,971.80. Following the completion of the transaction, the chief executive officer now owns 1,250,210 shares of the company’s stock, valued at $6,388,573.10. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 11.00% of the company’s stock.

About Anavex Life Sciences

(Free Report)

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.

Further Reading

Institutional Ownership by Quarter for Anavex Life Sciences (NASDAQ:AVXL)

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.